We recently published a list of the 11 Best Australian Stocks to Buy According to Analysts. In this article, we are going to take a look at where Alterity Therapeutics Limited (NASDAQ:ATHE) stands against other best Australian stocks to buy according to analysts.
Australia’s Economic Outlook for 2025
The tariffs announced by the United States have challenged the economic and market outlooks around the globe. On April 7, BlackRock released its quarterly review and outlook for the Australian economy. The report highlighted that the Reserve Bank of Australia (RBA) cut the cash rates to 4.10% after a 0.25% decrease during the first quarter of 2025. This was in line with the expectations, which pointed towards a more dovish approach in the upcoming quarters as well.
Market expectations before the tariffs were announced were that the RBA would reduce the rate by 0.25% in July 2025 and by another 0.25% in November. However, with tariffs in place and market uncertainty, the rate cuts are expected to be in effect sooner than expected. The report anticipates that the RBA will likely cut rates in May this year, followed by at least two more cuts in 2025. The bank decided to keep the rates unchanged during the latest April meeting, as per the report, this was due to the high level of uncertainty that remains around inflation. The data regarding inflation suggests that the underlying inflation continues to ease in line with the forecasts. During the April meeting, the RBA emphasized the importance of keeping the inflation around the midpoint of 2.5%, however, the current forecasts suggest that it will remain over 2.7%, thereby indicating potential rate cuts by the RBA.
In terms of GDP, the Real GDP came in above RBA forecasts during Q4 2024 after growing 1.3% year-over-year. The report attributed this growth to a recovery in household consumption and a strong public demand. Moreover, while the demand side remains healthy, the supply side has been constrained due to a weak labor productivity, indicated by unit labor cost rising 1.7% quarter-over-quarter.
The report also discussed the impact of tariffs on the Australian Economy. In 2024, Australia exported goods worth $24 billion to the United States. This was less than 1% of Australia’s GDP. If we take 2024 figures as a benchmark, this suggests that a 10% tariff on Australia can negatively impact the GDP by $2.4 billion. The report highlights that while the direct impact of tariffs might not be damaging for the economy, however, the indirect impact in terms of the global growth prospects and higher inflation can be risky. On the positive side, the RBA anticipates that tariffs on China can be helpful as it is likely to direct its exports to other markets, including Australia, resulting in local disinflation.
Our Methodology
To compile the list of 11 best Australian stocks to buy according to analysts, we used the Finviz stock screener and CNN. Using the screener, we aggregated a list of Australian stocks with an upside potential of more than 30%. We cross-checked each stock’s upside potential using CNN and ranked the stocks in ascending order. We have also added the hedge fund sentiment around each stock sourced from Insider Monkey’s Q4 2024 database. Please note that the data was collected on May 14, 2025.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
A medical research laboratory showcasing the latest technologies used in clinical-stage biopharmaceutical studies.
Alterity Therapeutics Limited (NASDAQ:ATHE)
Number of Hedge Fund Holders: 1
Analyst Upside Potential: 189.16%
Alterity Therapeutics Limited (NASDAQ:ATHE) is a clinical-stage biopharmaceutical company engaged in developing disease-modifying treatments for neurodegenerative diseases. Its lead candidate is ATH434, which is an oral small molecule designed to inhibit the aggregation of pathological proteins involved in neurodegeneration. ATH434 is being developed primarily to treat Parkinson’s disease and related Parkinsonian disorders.
On April 29, Alterity Therapeutics Limited (NASDAQ:ATHE) announced positive results from its ATH434-201 Phase 2 clinical trial. The placebo-controlled tests showed that ATH434 significantly slowed the clinical progression of Multiple System Atrophy. The 50 mg dosage showed a 48% reduction in disease progression at 52 weeks, and the 75 mg dose showed a 29% reduction at the same time point.
Moreover, on May 5, the company announced that it had been granted fast-track FDA approval for ATH434 to Treat Multiple System Atrophy. The fast track offers several benefits, including eligibility for accelerated approval and priority review if criteria are met, rolling review of the New Drug Application, and more frequent communication with the FDA. Alterity Therapeutics Limited (NASDAQ:ATHE) is one of the best Australian stocks to buy according to analysts.
Overall, ATHE ranks 3rd on our list of best Australian stocks to buy according to analysts. While we acknowledge the potential of ATHE to grow, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than ATHE but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.
